Clinical Trials Logo
  1. Home
  2. Invasive Pulmonary Aspergillosis
  3. NCT05138666

Non-invasive Tools to Diagnose Invasive Aspergillosis Infections in ICU Patients With COVID-19 and Other Conditions. — BM-ASP-ICU  

Invasive Pulmonary Aspergillosis Clinical Trial

Official title:
Non-invasive Tools to Better Diagnose Invasive Aspergillosis Infections in ICU Patients With COVID-19 and Other Non-immunosuppressive Conditions.

Clinical Trial Summary

Invasive aspergillosis (IA) are difficult to diagnose in the ICU population, as the patients often do not present the conventional risks factors of immunocompromised patients (EORTC/MSG criteria). In the ICU population, patients often present other risk factors, such as cirrhosis, COPD, influenza and currently SARS-Cov2. The clinicians are thus currently missing precise criteria to distinguish colonization from IA in these patients, while they need to decide if an antifungal treatment is necessary or not. A new algorithm, entitled BM ASP ICU, based on investigators field experience and the scientific literature, which takes into account both EORTC/MSG criteria and a combination of fungal biomarkers, was proposed recently by Haman et al, Annals Intensive Care, 2021. Additional serological assays (immunoprecipitation and ELISA) showed since their interest, especially concerning SARS-Cov2 patients, a new population at risk of IA in the ICU, which emerged in the past months. The present study aims at prospectively implementing the BM ASP ICU algorithm during two years in the routine practice of six ICU units distributed in general and teaching hospitals situated northeast of France. The BM ASP ICU algorithm would be completed by serological assays aiming at assessing a sensitization towards Aspergillus fumigatus. The investigators plan to include 400 ICU patients at risk of IA; SARS-Cov2 patients will be part of the cohort. A weekly screening including culture of respiratory samples, galactomannan antigen, fungal qPCRS (targeting A. fumigatus), and A. fumigatus serology will be applied for all included patients. The performance (sensitivity and specificity, likelihood ratios) of each fungal biomarkers, alone and in combination with others, will be assessed, for all patients, and also within subgroups of patients with specific risk factors (such as SARS-Cov2 for example). These results should lead to solid understanding of which combination of tests is optimal to diagnose IA and thus to initiate appropriate antifungal treatment. the investigators hope that this study will result in improved survival rate of ICU patients with IA.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05138666
Study type Interventional
Source Centre Hospitalier Universitaire de Besancon
Contact Laurence MILLON, MD
Phone 0370632353
Email lmillon@chu-besancon.fr
Status Recruiting
Phase N/A
Start date September 16, 2022
Completion date March 2024
View Details
See also
  Status Clinical Trial Phase
Completed NCT01782131 - A Study of the Safety and Efficacy of Posaconazole Versus Voriconazole for the Treatment of Invasive Aspergillosis (MK-5592-069) Phase 3
Not yet recruiting NCT02234739 - Voriconazole for IPA in Chinese Patients With COPD Phase 4
Completed NCT01615809 - Nebulized Amphotericin B Lipid Complex in Invasive Pulmonary Aspergillosis in Paediatric Patients With Acute Leukaemia Phase 2
Completed NCT04267497 - Nebulised Liposomal Amphotericin for Invasive Pulmonary Aspergillosis (NAIFI01 Study) Phase 1
Recruiting NCT05860387 - Early Diagnosis of Invasive Lung Aspergillosis
Withdrawn NCT01188759 - Voriconazole And Anidulafungin Combination For Invasive Aspergillosis In Pediatric Subjects Phase 3
Completed NCT00923832 - Early Molecular Detection for the Improved Diagnosis of Invasive Pulmonary Aspergillosis and Invasive Pulmonary Zygomycosis N/A
Recruiting NCT05982912 - VOC in Breath Samples for the Diagnosis of IPA
Not yet recruiting NCT02100761 - CYP 2C19 Polymorphism and Voriconazole Trough Concentration in Chinese Adult Patients N/A
Recruiting NCT00986713 - Value of Amphotericin B Inhalation for Prophylaxis of Invasive Pulmonary Aspergillosis After Renal Transplantation Phase 4
Recruiting NCT05569824 - LFD of Aspergillus Antigen in Paediatrics
Not yet recruiting NCT04848831 - Diagnosis of Invasive Pulmonary Aspergillosis, Specific Testing in Bronchial Secretions Versus Bronchoalveolar Fluid
Completed NCT04077697 - Clinical and Prognostic Comparisons Between Invasive Pulmonary Aspergillosis With or Without Invasive Tracheobronchitis During Severe Influenza: a Retrospective Multicenter Cohort Study.
Completed NCT03672292 - Study to Evaluate the Safety and Efficacy of the Coadministration of Ibrexafungerp (SCY-078) With Voriconazole in Patients With Invasive Pulmonary Aspergillosis Phase 2
Recruiting NCT01499433 - Efficacy and Safety of Caspofungin for Invasive Pulmonary Aspergillosis Underlying Chronic Obstructive Pulmonary Disease Phase 4
Completed NCT01247142 - Evaluation of Exhaled Breath Condensate in the Diagnosis of Invasive Pulmonary Aspergillosis N/A
Completed NCT00501098 - Prophylaxis of Fungal Invasive Infections in Leukemia Phase 2
Recruiting NCT03748069 - Influenza Associated Aspergillosis In-depth Investigation
Completed NCT02058316 - Bronchoalveolar Lavage Lateral-Flow Device Test for Invasive Pulmonary Aspergillosis: a Multicenter Study
Terminated NCT03327727 - VL-2397 Compared to Standard First-Line Treatment for Invasive Aspergillosis (IA) in Adults Phase 2